Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-60

I don't mean to pick on you (and thanks for the previous moderation ) but you're own links (refer below) don't align with the extreme conspiracy theories that so many resort to when there is a level of uncertainty (estimated in some studies to be up to 25% of the US population no including the Stop the Steal). Indeed, the medical profession and FDA have conflicts of interest, which by law must be disclosed. However, it doesn't mean their intent is to hold anyone back or create an unfair playing field. Our issues to date are mostly our own doing (not completing our own sets of 6) and I tend to shutter when PR claims PAR to already be "experts in repurposing" given its without any real justification.

Your own link showed remdesivir showed modest levels of mortality improvement and superior to placebo AE at the commencement of the COVID outbreak:

":.....The Kaplan–Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).

CONCLUSIONSOur data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection."